Suven to show Samelisant Phase 2 data at SLEEP-2026
Three posters on narcolepsy drug cover positive efficacy in daytime sleepiness, cataplexy study design, and Phase 3 plan. Conference runs June 14-17 in Baltimore.
— 3 earlier stories on Suven Life Sciences Ltd. →What's new
- Suven will present three posters on Samelisant at SLEEP-2026.
- Includes positive Phase 2 efficacy data for excessive daytime sleepiness.
- Also slated: Phase 2 cataplexy trial design and global Phase 3 AWAKE rationale.
Why this matters
Samelisant is Suven's lead narcolepsy asset and one of five clinical-stage CNS candidates. Presentation at a major sleep conference signals readiness to engage the specialty community and potential partners, but actual data details remain under wraps until the event.
What we're watching
- Full efficacy and safety data from Phase 2 when posters go live.
- Design and enrollment timeline for the Phase 3 AWAKE study.
- Any partnering discussions that emerge from the exhibit booth.
The full read
Suven Life Sciences is taking its narcolepsy drug Samelisant to a major stage. At the SLEEP-2026 conference in Baltimore (June 14-17), the company will present three posters: positive Phase 2 efficacy data for excessive daytime sleepiness, the design of a Phase 2 cataplexy study, and the rationale for a global Phase 3 AWAKE trial. The company also plans investigator and partner meetings on site. For a clinical-stage biopharma with ₹7,142 cr market cap and near-zero revenue, this is pipeline progress, not a binary event. The actual data will only be revealed at the conference, so the immediate market impact is limited. But the presentations signal that Suven is ready to engage the sleep community and potentially advance partnering discussions. Samelisant is one of five CNS assets; the most advanced, Masupirdine, recently cleared a Phase 3 safety check.
Questions answered
- What three posters is Suven presenting on Samelisant?
- One covers positive Phase 2 efficacy data for excessive daytime sleepiness. Another details the design of a Phase 2 study for cataplexy. The third lays out the rationale for the global Phase 3 AWAKE study.
- When and where is SLEEP-2026?
- The annual meeting takes place June 14-17, 2026, in Baltimore, Maryland.
- Is this a binary catalyst for Suven?
- No: it is a data presentation, not a regulatory approval or final readout. The details will influence scientific credibility and partnership interest, but the stock impact is likely muted until full data are disclosed.
- What else is in Suven's pipeline?
- Samelisant is one of five clinical-stage CNS assets. Others include Masupirdine for Alzheimer's agitation (Phase 3) and Ropanicant for major depressive disorder.
- Does Suven have any revenue or profit?
- Trailing revenue is about ₹2 crore per quarter with net losses of ₹46 crore. The company is a clinical-stage biopharma with no marketed products.
Suven Life Sciences Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on SUVEN →- 12 Jun 2026 · 11:25 AM IST Suven to show Samelisant Phase 2 data at SLEEP-2026
- today Suven's Ropanicant clears Phase 2b, cuts depression scores 3.6 points vs placebo
- 1d ago Suven's experimental cognitive drug clears Phase 1 safety hurdle
- 13d ago Suven's Alzheimer's drug passes a critical Phase 3 safety check.